中国广核(003816) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was approximately CNY 20.57 billion, a decrease of 5.63% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was approximately CNY 2.74 billion, down 5.08% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 2.70 billion, a decrease of 4.34% compared to the previous year[5]. - The net profit attributable to shareholders for the first nine months of 2023 was approximately CNY 9.70 billion, an increase of 10.36% year-on-year[10]. - The company reported a profit total of approximately CNY 18.39 billion for the first nine months of 2023, a 15.9% increase year-on-year[10]. - The net profit for Q3 2023 reached CNY 15,306,551,008.25, an increase of 16.9% compared to CNY 13,093,016,598.62 in Q3 2022[24]. - The company reported a total comprehensive income of CNY 15,532,670,340.23, compared to CNY 13,887,368,325.59 in the same period last year, marking an increase of 11.8%[25]. Earnings and Expenses - The basic earnings per share for Q3 2023 were CNY 0.0543, down 5.07% from the same period last year[5]. - The basic earnings per share for Q3 2023 were CNY 0.1921, up from CNY 0.1741 in Q3 2022, representing an increase of 10.3%[25]. - The financial expenses decreased to CNY 4,228,087,066.00 from CNY 5,019,025,800.16, a reduction of approximately 15.7%[24]. - The company's tax expenses for the quarter were CNY 3,086,208,691.92, an increase from CNY 2,772,871,727.35, indicating a rise of 11.3%[24]. - Cash paid for employee compensation rose to CNY 6.77 billion, compared to CNY 6.52 billion, reflecting an increase of about 3.8%[27]. Assets and Liabilities - The total assets at the end of Q3 2023 were approximately CNY 413.94 billion, reflecting a 1.20% increase from the end of the previous year[5]. - Current assets as of September 30, 2023, amounted to ¥73,747,661,431.10, up from ¥70,504,910,095.09 at the beginning of the year, indicating an increase of approximately 3.2%[21]. - Non-current assets totaled ¥340,191,522,979.52, a slight increase from ¥338,510,989,910.52 at the beginning of the year, representing a growth of approximately 0.5%[21]. - The total assets of the company reached ¥413,939,184,410.62, compared to ¥409,015,900,005.61 at the start of the year, indicating an increase of about 1.0%[22]. Cash Flow - Cash received from operating activities rose by 39.78% to 207,417.69 million CNY, attributed to an increase in project bidding guarantees received[13]. - The cash flow from operating activities was CNY 68,593,824,027.39, compared to CNY 64,314,145,662.03 in the previous year, showing an increase of about 6%[26]. - Operating cash inflow totaled CNY 71.63 billion, an increase from CNY 67.01 billion year-over-year, reflecting a growth of approximately 4.0%[27]. - Net cash flow from operating activities reached CNY 26.99 billion, up from CNY 24.33 billion, representing a year-over-year increase of about 10.9%[27]. - The total cash and cash equivalents at the end of the period stood at CNY 10.60 billion, down from CNY 12.42 billion year-over-year, a decrease of about 14.6%[27]. Investments and Subsidies - The company received government subsidies amounting to CNY 4.49 million during the reporting period, primarily related to research projects[7]. - Investment income received increased by 60.48% to 111,501.85 million CNY, mainly due to higher cash dividends from joint ventures[13]. - The company reported an increase in cash received from investment income to CNY 1.12 billion, up from CNY 0.69 billion, marking a growth of approximately 60.8%[27]. Operational Developments - The company received approval for the construction of the Ningde Units 5 and 6 on July 31, 2023[17]. - Construction of the Lufeng Unit 6 commenced on August 26, 2023, entering the civil construction phase[18]. - The company completed the election of the fourth board of directors and supervisory board on October 9, 2023[19]. Research and Development - Research and development expenses increased to CNY 1,043,574,905.47, up from CNY 885,729,260.83, reflecting a growth of 18% year-over-year[24]. Market Outlook - Future outlook includes continued focus on market expansion and potential new product development, although specific details were not provided in the earnings call[22].